Recruitment status changed
Before: Active not recruiting. After: Terminated.
Among the trials TrialRedline tracks, 76 changed their ClinicalTrials.gov record in December 2025: 4 status changes to terminated, withdrawn or suspended, 12 primary outcome text edits, 16 completion dates moved later, 23 enrollment changes, 36 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.
4 in December 2025. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.
Before: Active not recruiting. After: Terminated.
Before: Recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Recruiting. After: Terminated.
12 in December 2025. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Absolute change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score. After: Measure: Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Hamilton Anxiety Scale. After: Measure: Hamilton Anxiety Scale (HAM-A) Score.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in hepatic fat fraction assessed by MRI-PDFF. After: Measure: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) in Cohort 1. After: Measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) Without Caregiver Input in Cohort 1.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. Measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs.. After: Measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. Measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs Measure: Incidence of treatment-emergent AEs and SAEs Measure: Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drug.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following 2 different dose levels of MBX 1416.. After: Measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of Participants With Adverse Events (AEs). After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of adverse events observed during dosing of CK--3773274 in patients with HCM. After: Measure: Incidence of Adverse Events (AEs) Measure: Incidence of Left Ventricular Ejection Fraction (LVEF) < 50% Measure: Incidence of Serious Adverse Events (SAEs).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1) Measure: Duration of Overall Survival (OS). After: Measure: Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC) Measure: Duration of Overall Survival (OS).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Ocular Pain at Visit 4.. After: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Pain at Visit 4..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mean Percentage Change in LDL-C From Baseline To Week 12. After: Measure: Mean Percent Change in LDL-C From Baseline To Week 12.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Main Study and Extension Study - Treatment-Emergent Adverse Events. After: Measure: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Measure: Number of Participants With Clinically Significant Changes in Chemistry Parameters Measure: Number of Participants With Clinically Significant Changes in Hematology Parameters Measure: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters.
16 in December 2025. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.
Before: 28 Feb 2025. After: 28 Feb 2027.
NCT05023018 · Neonc Technologies, Inc.
Before: 30 Sep 2025. After: 30 Dec 2026.
Before: 31 Mar 2026. After: 31 Mar 2027.
Before: 30 Jun 2025. After: 30 Jun 2026.
Before: 15 Jan 2026. After: 15 Jan 2027.
Before: 8 Mar 2021. After: 30 Nov 2021.
Before: 1 Dec 2025. After: 31 Jul 2026.
Before: 28 Feb 2025. After: 29 Apr 2025.
Before: 16 Oct 2024. After: 27 Nov 2024.
Before: Jan 2026. After: Jun 2026.
Before: Apr 2030. After: Jul 2030.
Before: Sep 2025. After: Sep 2028.
Before: Oct 2025. After: Feb 2026.
Before: Nov 2025. After: Mar 2026.
Before: Dec 2025. After: Jun 2026.
Before: Aug 2026. After: Sep 2026.
23 in December 2025. The participant count changed. Planned and actual counts are shown as recorded. Newest first.
Before: 190 participants (planned). After: 212 participants (actual).
Before: 474 participants (planned). After: 594 participants (actual).
Before: 102 participants (actual). After: 101 participants (actual).
Before: 210 participants (planned). After: 158 participants (planned).
Before: 249 participants (actual). After: 279 participants (planned).
Before: 48 participants (planned). After: 46 participants (actual).
Before: 120 participants (planned). After: 140 participants (actual).
Before: 54 participants (planned). After: 30 participants (actual).
Before: 200 participants (planned). After: 230 participants (planned).
Before: 15 participants (planned). After: 16 participants (actual).
Before: 55 participants (planned). After: 15 participants (actual).
Before: 10 participants (planned). After: 4 participants (actual).
Before: 460 participants (planned). After: 501 participants (actual).
Before: 1499 participants (actual). After: 1514 participants (actual).
Before: 225 participants (planned). After: 180 participants (planned).
Before: 100 participants (planned). After: 101 participants (actual).
Before: 178 participants (actual). After: 220 participants (actual).
Before: 180 participants (planned). After: 225 participants (planned).
Before: 320 participants (planned). After: 327 participants (actual).
Before: 60 participants (planned). After: 71 participants (actual).
Before: 82 participants (planned). After: 87 participants (actual).
Before: 765 participants (planned). After: 1200 participants (planned).
Before: 800 participants (planned). After: 885 participants (actual).
36 in December 2025. Any other change of recruitment status, such as recruiting to completed. Newest first.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Enrolling by invitation.
Before: Active not recruiting. After: Completed.
Before: Active not recruiting. After: Enrolling by invitation.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Enrolling by invitation.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Showing 25 of 36. Browse all tracked trials to open the rest.
TrialRedline, “Clinical trial registry changes: December 2025”. https://trialredline.com/reports/2025-12
Based on public ClinicalTrials.gov record history. How we collect and check the data